



Quality For All

Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt's First Lactase Enzyme Supplement for the treatment of Lactose Intolerance

28 May 2024 | Cairo, Egypt

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. ("Rameda" or the "Group"), a leading Egyptian pharmaceutical company, is pleased to announce the launch of Ramelact, marking a significant step forward in its commitment to expand its freely priced product portfolio. Ramelact is the first lactase enzyme specifically designed for adults in Egypt, addressing the widespread issue of lactose intolerance.

Lactose intolerance affects a staggering 68% of Egypt's population, causing digestive discomfort and hindering the enjoyment of dairy products. Ramelact offers a solution formulated with Tilactase, an enzyme that effectively breaks down lactose, alleviating symptoms and allowing individuals to tolerate dairy without complications.

Ramelact is now available over the counter in pharmacies across Egypt, providing patients with convenient and direct access to address their lactose intolerance. This launch aligns with Rameda's strategic focus on expanding its freely priced offerings to meet the evolving needs of customers. The public price for Ramelact is set at EGP 360 for a pack containing 30 tablets.

"The launch of Ramelact underscores our commitment to both broadening our freely priced portfolio and delivering new and up to date medications that improve patient well-being," stated Dr. Amr Morsy, CEO of Rameda. "Ramelact has the potential to significantly enhance the lives of countless Egyptians struggling with lactose intolerance."

The market for lactose intolerance treatments is still untapped and is expected to experience significant growth, and Ramelact is poised to become a leader in this space. The active ingredient, Tilactase, boasts a remarkable compounded annual growth rate (CAGR) of 195% between 2019 and 2023 (4-year CAGR) and 107% for the past two years (2-year CAGR). This impressive growth trajectory signifies the increasing demand for Tilactase-based solutions in managing lactose intolerance. Rameda's strategic vision in addressing this unmet medical need, coupled with the efficacy of the product, positions Ramelact for exceptional success.

-Ends-



Quality For All

Investor Relations Contact:

Khaled Daader
Head of Mergers and Acquisitions and Investor Relations
Email : khaled.daader@rameda.com

About Rameda

Established in 1986, Rameda (RMDA.CA on EGX) is a leading Egyptian pharmaceutical company led by a team of professionals with extensive multinational experience. The company develops and produces a wide range of branded generic pharmaceuticals, nutraceuticals, food supplements and veterinary products. Rameda combines global standards with local insights and a customer-centric approach. It has developed a broad portfolio of products across multiple therapeutic areas by successfully leveraging its strong product portfolio with its accretive product acquisitions to become one of the fastest-growing pharmaceutical players in Egypt. The company produces its wide range of dosage forms at its three manufacturing facilities located at its industrial complex in Cairo's Sixth of October Industrial Zone.

Forward-Looking Statements

This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as "according to estimates", "anticipates", "assumes", "believes", "could", "estimates", "expects", "intends", "is of the opinion", "may", "plans", "potential", "predicts", "projects", "should", "to the knowledge of", "will", "would", or, in each case, their negatives, or other similar expressions that are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding our business and management, our future growth or profitability and general economic and regulatory conditions and other matters affecting us.

Forward-looking statements reflect our management's ("Management") current views of future events, are based on Management's assumptions, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. The occurrence or non-occurrence of an assumption could cause our actual financial condition and results of operations to differ materially from, or fail to meet expectations expressed or implied by, such forward-looking statements. Our business is subject to a number of risks and uncertainties that could also cause a forward-looking statement, estimate, or prediction to become inaccurate. These risks include fluctuations in the prices of raw materials or employee costs required by our operations, its ability to retain the services of certain key employees, its ability to compete successfully, changes in political, social, legal, or economic conditions in Egypt, worldwide economic trends, the impact of war and terrorist activity, inflation, interest rate and exchange rate fluctuations, and Management's ability to timely and accurately identify future risks to our business and manage the risks mentioned above. Certain figures contained in this document, including financial information, have been subject to rounding adjustments. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this document may not conform exactly to the total figure given.